Bio Vitos Pharma AB receives observation status

Published

Yesterday, on April 15, 2024, Bio Vitos Pharma AB (the “Company”) issued a press release with information that a member of the Company’s board of directors had resigned, resulting in the board of directors consisting of only two members.

The rules of Nasdaq First North Growth Market state that an issuer can be given observation status if any circumstance exists that results in substantial uncertainty regarding the issuer or the pricing of its financial instruments.

With reference to the above, Nasdaq Stockholm AB decides that the shares in Bio Vitos Pharma AB (BIOVIT, ISIN code SE0009320278, order book ID 135098) shall be given observation status.

For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50.  

Nasdaq Stockholm AB